BLAINJECTION
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NUFYMCO (ranibizumab-leyk) by Formycon is vegf-a, including the biologically active, cleaved form of this molecule, vegf110. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUFYMCO is a monoclonal antibody biosimilar of ranibizumab-leyk indicated for retinal and ophthalmic conditions. It is a VEFG inhibitor administered via intravitreal injection to reduce pathologic neovascularization and fluid accumulation. This is a recently approved biosimilar entering a competitive anti-VEGF landscape.
Launch
New market entrant with moderate competitive pressure; early-stage team building likely underway to establish market presence in ophthalmology.
Mechanism of Action
VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NUFYMCO offers exposure to biosimilar commercialization strategy in a high-value indication with established market dynamics. Career growth depends on rapid market share capture and physician adoption in an ophthalmology-specialized environment.
Brand Manager
Worked on NUFYMCO at Formycon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.